Baseline TT2 patient characteristics according to TP53-regulated gene cluster
| Characteristic . | Cluster 1, % (n = 98) . | Cluster 2, % (n = 253) . | P† . |
|---|---|---|---|
| Age at least 65 y | 21 | 22 | NS |
| Female sex | 42 | 44 | NS |
| White race | 91 | 88 | NS |
| IgA isotype | 30 | 24 | NS |
| Creatinine at least 2.0 mg/dL | 19 | 9 | .011 |
| MRI focal bone lesions, at least 3 | 72 | 53 | .001 |
| C-reactive protein at least 4.0 mg/L | 45 | 32 | .023 |
| Lactate dehydrogenase at least 190 IU/L | 44 | 30 | .017 |
| β2-microglobulin at least 4.0 mg/L | 38 | 33 | NS |
| Albumin less than 3.5 g/dL | 45 | 33 | .041 |
| Hemoglobin less than 10 g/dL | 31 | 23 | NS |
| Bone marrow plasma cells (by aspiration) at least 33% | 47 | 56 | NS |
| Chromosomal abnormalities (defined by G-banding) | 48 | 30 | .002 |
| Deletion of chromosome 13 | 66 | 43 | < .001 |
| Amplification of chromosome 1q21 | 65 | 36 | .002 |
| High-risk model (17-gene)* | 36 | 7 | < .001 |
| Subgroups with poor prognosis* (Proliferation/MMSET/FGFR3/MAF/MAFB) | 50 | 51 | NS |
| Characteristic . | Cluster 1, % (n = 98) . | Cluster 2, % (n = 253) . | P† . |
|---|---|---|---|
| Age at least 65 y | 21 | 22 | NS |
| Female sex | 42 | 44 | NS |
| White race | 91 | 88 | NS |
| IgA isotype | 30 | 24 | NS |
| Creatinine at least 2.0 mg/dL | 19 | 9 | .011 |
| MRI focal bone lesions, at least 3 | 72 | 53 | .001 |
| C-reactive protein at least 4.0 mg/L | 45 | 32 | .023 |
| Lactate dehydrogenase at least 190 IU/L | 44 | 30 | .017 |
| β2-microglobulin at least 4.0 mg/L | 38 | 33 | NS |
| Albumin less than 3.5 g/dL | 45 | 33 | .041 |
| Hemoglobin less than 10 g/dL | 31 | 23 | NS |
| Bone marrow plasma cells (by aspiration) at least 33% | 47 | 56 | NS |
| Chromosomal abnormalities (defined by G-banding) | 48 | 30 | .002 |
| Deletion of chromosome 13 | 66 | 43 | < .001 |
| Amplification of chromosome 1q21 | 65 | 36 | .002 |
| High-risk model (17-gene)* | 36 | 7 | < .001 |
| Subgroups with poor prognosis* (Proliferation/MMSET/FGFR3/MAF/MAFB) | 50 | 51 | NS |
NS indicates not significant.
High-risk model1 and PR/MS/MF subgroup designation25 have been described elsewhere.
χ2 was used to compare the clinical and biologic parameters between cases in hierarchical cluster 1 (correlated with low TP53 expression) and cluster 2 (correlated with high TP53 expression).